Risultati di ricerca
3 giu 2024 · JAMA Oncol. Published online June 3, 2024. doi:10.1001/jamaoncol.2024.2744 This cohort study assesses potential reductions in greenhouse gas emissions and downstream health harms associated with telemedicine and fully decentralized cancer care.
- Cardiovascular Risk in Prostate Cancer
In JAMA Oncology, El-Taji et al 1 report the results of a...
- Journals
Neoadjuvant Nivolumab Plus Chemotherapy Followed By...
- Cardiovascular Risk in Prostate Cancer
6 giu 2024 · In JAMA Oncology, El-Taji et al 1 report the results of a contemporary systematic review and meta-analysis of 24 randomized clinical trials to assess the cardiovascular (CV) impact of androgen receptor signaling inhibitors (ARSIs) across the M0 to M1 hormone-sensitive prostate cancer (HSPC) and castration-resistant prostate cancer ...
6 giu 2024 · Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Clinical Trial | Targeted and Immune Therapy | JAMA Oncology | JAMA Network. Original Investigation. June 6, 2024.
6 giorni fa · JOURNAL ARTICLE. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer: A Nonrandomized Controlled Trial.
10 giu 2024 · Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Read More About ASCO.
A 45-year-old woman was evaluated in the oncology clinic of the hospital because of metastatic triple-negative breast cancer that had progressed despite chemotherapy. Management decisions were...
29 mag 2024 · Background: Ivonescimab (AK112/SMT112) is a anti-PD-1/VEGF bispecific antibody. Previous phase I/II clinical studies have shown potential efficacy of ivonescimab in NSCLC patients with EGFR mutations who had failed prior EGFR-TKIs therapies.
